Skip to main content

Table 3 Variables associated with total ASES score across time, based on multivariate linear mixed models

From: Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis

Variable Coefficient (95% CI) p-value Conditional R2 Interactions
DAS28-CRP −0.22 (−0.32, −0.11) <0.001 0.614 HAQ*
HAQ −1.06 (−1.27, −0.84) <0.001 0.610 -
Pain (VAS) −0.14 (−0.19, −0.09) <0.001 0.603 -
Fatigue (VAS) −0.15 (−0.19, −0.10) <0.001 0.606 -
PGA (VAS) −0.16 (−0.21, −0.11) <0.001 0.594 -
SF-36 MCS 0.40 (0.29, 0.50) <0.001 0.607 -
IPQ-R illness coherence 0.12 (0.09, 0.15) <0.001 0.617 -
IPQ-R treatment control 0.16 (0.12, 0.20) <0.001 0.619 -
IPQ-R personal control 0.09 (0.06, 0.11) <0.001 0.608 -
IPQ-R consequences −0.17 (−0.19, −0.15) <0.001 0.690 -
IPQ-R emotional representations −0.11 (−0.12, −0.09) <0.001 0.634 -
RAQoL −0.11 (−0.12, −0.09) <0.001 0.640 HAQ**
PhGA (VAS) −0.12 (−0.19, −0.04) 0.002 0.613 -
TJC28 −0.01 (−0.06, 0.03) 0.590 0.594 -
SJC28 0.01 (−0.04, 0.07) 0.630 0.594 -
CRP 0.00 (−0.01, 0.01) 0.550 0.594 -
ESR 0.00 (0.00, 0.01) 0.320 0.597 -
  1. Bonferroni correction for multiple comparisons was applied, setting the significance level at p < 0.003
  2. *Interaction (ß = 0.24; 95% CI = 0.12–0.36; p < 0.001) implies that the additional effect of DAS28-CRP on self-efficacy (SE) decreases with increasing HAQ
  3. **Interaction (ß = 0.05; 95% CI = 0.03–0.08; p < 0.001) implies that the additional effect of RAQoL on SE decreases with increasing HAQ
  4. ASES Arthritis Self-Efficacy Scale, DAS28 Disease Activity Score in 28 joints, HAQ Health Assessment Questionnaire, VAS visual analogue scale, PGA patient’s global assessment of disease activity, SF-36 MCS Short-Form 36 mental component score, IPQ-R Revised Illness Perception Questionnaire, PhGA physician’s global assessment of disease activity, TJC28 tender joint count in 28 joints, SJC28 swollen joint count in 28 joints, CRP C-reactive protein, ESR erythrocyte sedimentation rate